Please sign in to follow a disease.
New cholesterol drug could prevent thousands of heart attacks, study suggests
NCT ID NCT07214857
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study used national health survey data to estimate how many US adults with high cholesterol might be eligible for a new drug called inclisiran. Researchers also calculated how many heart attacks and strokes could be prevented over 10 years if these patients took the drug. The study did not give inclisiran to anyone—it was a computer-based analysis using existing health records.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- inclisiran
- What this could lead to
- If the estimates are accurate, this could show that inclisiran might prevent thousands of heart attacks and strokes in eligible patients.
- What could go wrong
- This is a modeling study based on surveys, not a clinical trial testing the drug directly. Real-world results may differ, and inclisiran's actual effectiveness and safety are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,385 people
The number who actually took part.
- Started
-
Mar 2024
- Finished
-
Oct 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This was a cross-sectional, non-interventional cohort study.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: * Aged 18 years of age or older * Elevated LDL-C despite statin therapy * Other inclusion criteria per ongoing inclisiran clinical trials
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atherosclerotic cardiovascular disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI read heart scans to predict the next heart attack?
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?
- Vitamin B3 supplement put to the test against psoriasis inflammation
- Can calming inflammation shield the heart?
- Could artery disease drain the body's repair cells?
- Can hidden blood mutations ignite heart disease?